IO Biotech Inc

詳細情報 IO Biotech Inc 企業名

IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

企業情報

企業コードIOBT

会社名IO Biotech Inc

上場日Nov 05, 2021

最高経営責任者「CEO」Dr. Mai-Britt Zocca, Ph.D.

従業員数80

証券種類Ordinary Share

決算期末Nov 05

本社所在地Ole Maaloes Veh 3

都市COPENHAGEN

証券取引所NASDAQ Global Select Consolidated

国Denmark

郵便番号2200

電話番号4570702980

ウェブサイトhttps://www.iobiotech.com/

企業コードIOBT

上場日Nov 05, 2021

最高経営責任者「CEO」Dr. Mai-Britt Zocca, Ph.D.

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Mai-Britt Zocca, Ph.D.

President, Chief Executive Officer, Founder, Director

76.47K

--

Mr. Devin Whittemore Smith

General Counsel, Company Secretary

16.93K

+243.31%

Ms. Heidi Hunter

Independent Director

15.00K

--

Mr. Brian Burkavage

Chief Accounting Officer, Vice President - Finance

11.50K

+666.67%

Dr. Helen Louise Collins, M.D.

Director

--

Ms. Kathleen Sereda Glaub

Independent Director

--

Dr. Christian E. Elling, Ph.D.

Independent Director

--

Dr. Peter Hirth, Ph.D.

Chairman of the Board

--

Mr. David V. Smith

Independent Director

--

Dr. Faical Miyara, Ph.D.

Chief Business Officer

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Mai-Britt Zocca, Ph.D.

President, Chief Executive Officer, Founder, Director

76.47K

--

Mr. Devin Whittemore Smith

General Counsel, Company Secretary

16.93K

+243.31%

Ms. Heidi Hunter

Independent Director

15.00K

--

Mr. Brian Burkavage

Chief Accounting Officer, Vice President - Finance

11.50K

+666.67%

Dr. Helen Louise Collins, M.D.

Director

--

Ms. Kathleen Sereda Glaub

Independent Director

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Sat, Aug 23

株主統計

種類

株主統計

比率

Lundbeckfond Ventures

21.18%

Kurma Partners SA

10.35%

Vivo Capital, LLC

9.37%

HBM Partners AG

5.99%

Novo Holdings A/S

3.81%

他の

49.30%

株主統計

比率

Lundbeckfond Ventures

21.18%

Kurma Partners SA

10.35%

Vivo Capital, LLC

9.37%

HBM Partners AG

5.99%

Novo Holdings A/S

3.81%

他の

49.30%

種類

株主統計

比率

Venture Capital

46.07%

Investment Advisor

7.71%

Hedge Fund

4.10%

Investment Advisor/Hedge Fund

3.46%

Research Firm

2.49%

Individual Investor

0.34%

他の

35.83%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

52

43.99M

66.77%

-12.21M

2025Q1

56

44.00M

66.79%

+640.94K

2024Q4

57

44.61M

67.71%

+1.88M

2024Q3

50

48.46M

73.56%

+5.16M

2024Q2

48

51.73M

78.53%

+7.90M

2024Q1

53

52.99M

80.43%

+6.73M

2023Q4

55

54.27M

82.38%

+8.45M

2023Q3

56

56.33M

89.04%

+20.70M

2023Q2

46

22.57M

78.34%

-5.75M

2023Q1

42

24.23M

84.91%

+7.02M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Lundbeckfond Ventures

13.95M

21.18%

--

Apr 11, 2025

Kurma Partners SA

6.82M

10.35%

--

Apr 11, 2025

Vivo Capital, LLC

6.17M

9.37%

--

Apr 11, 2025

HBM Partners AG

3.94M

5.99%

--

Apr 11, 2025

Novo Holdings A/S

3.35M

5.09%

--

Mar 31, 2025

Marshall Wace LLP

2.11M

3.2%

--

Mar 31, 2025

PFM Health Sciences, LP

2.34M

3.55%

--

Mar 31, 2025

BofA Global Research (US)

1.65M

2.51%

--

Mar 31, 2025

Pivotal Bioventure Partners Investment Advisor LLC

864.20K

1.31%

--

Mar 31, 2025

Morgan Stanley Smith Barney LLC

789.46K

1.2%

-69.71K

-8.11%

Mar 31, 2025

詳細を見る

1.560USD

IO Biotech Inc

1.560

概要

企業名

金融

分析